SCHEMBL14198150

SCHEMBL14198150

CCN(C)C1Cc2ccc(Cl)cc2C1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 8/20 0.55
DRD3 P35462 8/20 0.55
DRD4 P21917 5/20 0.55
METAP1 P53582 1/20 0.40
NOS3 P29474 2/20 0.38
NOS1 P29475 2/20 0.38
NOS2 P35228 2/20 0.38
PNMT P11086 3/20 0.37
SLC6A4 P31645 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HTR1A P08908 1/20 0.37
ADRB2 P07550 1/20 0.37
CYP2D6 P10635 1/20 0.37
CASP1 P29466 1/20 0.37
SLC6A3 Q01959 1/20 0.37
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11462012 0.82 DRD2 (0.50) DRD2DRD3DRD4PNMTHTR1A
SCHEMBL12125958 0.77 DRD3 (0.57) DRD2DRD3DRD4SLC6A4HTR1A
SCHEMBL14198151 0.77 DRD2 (0.56) DRD2DRD3DRD4METAP1
SCHEMBL1025788 0.76 TSHR (0.41) DRD2DRD3DRD4SLC6A4
SCHEMBL11529541 0.74 HTR2A (0.41) DRD2DRD3DRD4METAP1PNMT
Aniline SCHEMBL27296362 0.73 DRD3 (0.46) DRD2DRD3DRD4SLC6A4HTR1A
SCHEMBL14878929 0.73 PNMT (0.55) DRD2DRD3DRD4PNMT
SCHEMBL24242574 0.71 SLC6A4 (0.47) PNMTSLC6A4HTR1A
SCHEMBL14346890 0.71 SLC6A4 (0.47) PNMTSLC6A4HTR1A
SCHEMBL14198136 0.70 DRD2 (0.43) DRD2DRD3DRD4PNMTSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7354946-B2 prominent growth inhibitory activity against tumor cells; cyclin dependent kinase inhibitors; colon cancer; N'-(3-t-butylisoindolino[3,2-b]oxazolidin-4-on-8-yl)-N-(4-(N-benzylpyrrolidin-3-yl)pyridin-2-yl)urea BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-08 US disclosed
US-7354946-B2 prominent growth inhibitory activity against tumor cells; cyclin dependent kinase inhibitors; colon cancer; N'-(3-t-butylisoindolino[3,2-b]oxazolidin-4-on-8-yl)-N-(4-(N-benzylpyrrolidin-3-yl)pyridin-2-yl)urea BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-08 US disclosed
US-20070027147-A1 Biarylurea derivatives MSD K.K. (JP) 2007-02-01 US disclosed
US-20070027147-A1 Biarylurea derivatives MSD K.K. (JP) 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027147-A1 Biarylurea derivatives CDK6, CDK4, CCNI DRD2 1883/4885DRD3 1909/4885DRD4 1568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.